Archives: MFN News Items

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group’s quarterly report Q3, July-September 2022

iZafe Group AB (publ.) – presents today, November 7, its report for the third quarter of 2022.

Summary of financial performance

  • Net sales for the quarter amounted to SEK 75 (38) thousand. The quarter's net sales consist of revenues related to the sale of the digital pharmaceutical robot Dosell.
  • Operating profit for the quarter amounted to SEK -5,680 (-5,342) thousand.
  • Profit after financial items for the quarter amounted to SEK -5,751 (-6,183) thousand.
  • Cash flow for the period amounted to SEK -4,513 (-6,475) thousand.
  • Earnings per share for the quarter before / after dilution amounted to SEK -0.1 (-0.2).
  • Equity per share at the end of the period amounted to SEK 0.3 (1.5).
  • The equity ratio at the end of the period was 75.0 (62.3) percent.

Significant events during the quarter

  • The company has signed a cooperation agreement with the welfare platform Avanto Care. The collaboration means that iZafe's products are integrated with Avanto Care's platform and gives the opportunity to work more proactively with the users' medication.
  • With our partners Careium AS and Hepro AS, 20 and 25 Dosell have respectively been implemented in new municipalities in Norway.
  • Together with Aleris, the Company has started a pilot project for safer medication management. The goal is to introduce Dosell for the patient group that has advanced healthcare at home. During the quarter, 30 patients were introduced to the pharmaceutical robot.

Significant events after the end of the quarter

  • During quarter four 2022, 12,075,688 warrants of series TO10B were exercised, representing approximately 34.1 percent of outstanding warrants. The subscription price amounted to SEK 0.26 per B-share and raised approximately SEK 3.1 million for the company before issue costs
  • The company has signed a cooperation agreement with Medcam AB, which sells medical devices to the healthcare sector in the Nordic region and Europe. The primary focus will be on the Dutch market, but the potential for the company to enter several countries exists in the near future.

COMMENTS FROM THE CEO
A lot has happened in the last quarter and we continue to make strides on our growth journey – both in the Swedish and European markets.
There is a growing demand for products and services that enable more digital care where medication and adherence are crucial.

Our Dosell vending machine continues to do well across the board and we are pleased to see strong demand and positive sales for Dosell consumer through Apoteket AB. The packaging and sales of our consumer product have been crucial in moving forward in dialogues with potential partners in other European countries. We have now accumulated enough experience and documentation to streamline the processes and reduce the costs associated with selling and marketing Dosell to consumers.

Our entire business concept is based on sales through specific partners who handle sales, warehousing, logistics and marketing. With a focus on ensuring quality in small volumes at first, we will be able to scale up the volume and sales of many of our partners in more markets as early as next year.
We have also started the implementation of Dosell at Aleris ASIH (Advanced Home Healthcare) which is very exciting. The whole ASIH market relies on a different type of Dosell than the procured Dosell at regional level. It has a different design that makes it very difficult for the drug robots to handle. We can proudly say that we are the only pharmaceutical robot on the Swedish market that can handle these dose bags.

We have a clear vision to offer proactive holistic health for many more providers and patients, with a focus on these four elements:

  1. Securing established and professional owners who can support the company with long-term external funding
  2. Strategic acquisitions that broaden our offering and portfolio ensuring the right medicine at the right time
  3. 3.Managing personal data and ensuring that the necessary integration work is implemented
  4. Internationalization towards new markets and together with both existing and new partners

Since October, we have a new Board in place that will help us to realize the action plan ahead. We have secured expertise and networks around finance, digitization, GDPR, sensitive data management and legal requirements. There we now have a clear strategy and plan for acquisitions, integrations with other wellbeing platforms, sales and internationalization.

The potential acquisition of Pilloxa is very interesting as we see that there is a strong demand around the ability to ensure adherence through all stages of the patient journey and to be able to integrate data into wellbeing platforms and home monitoring. The status on this is that we have completed due diligence and are now in the final stages of negotiations.

Another milestone during the quarter is our entry into the Dutch market. The Netherlands is an important market for us as they are the foremost pioneers in dose packaged medicine. The majority of all manufacturers of dose packaging machines are based in the Netherlands, which means that once we have been successful there, there will be positive knock-on effects throughout Europe.

Finally, I would like to mention that we are in dialogue with several other players in key markets in Europe, with whom we hope to have a clear agreement shortly. In this way, iZafe can in the future contribute broadly to a more proactive holistic approach to health, resulting in better health for more people. Socially sustainable value for society – that's really important.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-07 08:30 CET.

Attachments

IZafe Group Q3 ENG

IZafe Group Q3 ENG

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with Medcam AB, which sells medical technology products to healthcare in the Nordics and Europe. In the first place, the focus will be on the Dutch market, but the company has the potential for several countries in the near term.

"We have a high demand for products that enable a more digital healthcare where medication and compliance are an important factor. The pharmaceutical robot Dosell is a perfect complement to this, ensuring compliance in a safe way, while being integrated to enable more proactive and digital care.
The Dutch market has very great potential and we are starting this collaboration, as the demand from our customers is high for pharmaceutical robots", says Robert Camara, CEO of Medcam.

"The Dutch market has long been a goal for us to enter, as it is the country that has come the furthest in Europe regarding medication in sachets. We are now ready to start more collaborations that enable us to expand to several markets and look forward to starting work with Medcam and their customers", says Anders Segerström, CEO of iZafe Group.

About Medcam
MedCam AB markets and sells medical technology products and focuses on high quality products from stable suppliers. The company's business concept is to supply the Nordic and European market with high-quality products at good prices with high service.
The company's suppliers are located all over the world, i.a. USA, France, Germany and China. Medcam constantly strives to be able to satisfy customers' needs and demand and continuously searches the market, in order to be able to offer better and innovative products now and for the future.
For more information, read more at www.medcam.se

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were exercised, corresponding to approximately 34.1 percent of the total number of outstanding warrants of series TO10B, for subscription of 12,072,688 B-shares at a subscription price of SEK 0.26 per B-share. iZafe will receive approximately SEK 3.14 million before issuing costs through the exercise of the warrants of series TO10B.

Background
The subscription period for exercise of the warrants of series TO10B took place from September 27, 2022, up to and including October 11, 2022. The subscription price per B-share for exercising the warrants of series TO10B was set to SEK 0.26.

In total, 12,072,688 warrants of series TO10B were exercised for subscription of 12,072,688 B-shares, meaning that approximately 34.1 percent of all outstanding warrants of series TO10B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO10B, the number of shares in iZafe increases by 12,072,688 B-shares, from 70,874,308 shares (consisting of 600,000 A-shares och 70,274,308
B-shares) to a total of 82,946,996 shares. The share capital will increase by SEK 2,414,537.60 from SEK 14,174,861.60 to SEK 16,589,399.20.

For existing shareholders who did not exercise any warrants of series TO10B, the dilution amounts to approximately 14.6 percent of the number of shares and approximately 13.7 percent of the number of votes in the Company.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-10-13 07:20 CEST.

Attachments

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe and Aleris start pilot projects for safer medication

iZafe Group AB (publ.) announces today that it is starting a pilot project with Aleris. The aim of the project is to produce decision-making material for a potential introduction of the pharmaceutical robot Dosell in Aleris for the patient group advanced healthcare in the home (ASIH

In October will 30 patients in the advanced home healthcare, in Region Stockholm, will receive for the first time a robot that will help them take their medicine. The aim is to reduce the risk of medication mistreatment, underdosing and overdosing or mixing up medication. In some cases, the risk of abuse can also be reduced.

— Pharmaceutical robots mean major positive changes for patient safety. If the patient does not take their medication, an alarm is sent to our nurses, says Maria Frick, registered pharmacist at Aleri's local health care.

Aleris has investigated the possibility of introducing so-called pharmaceutical robots within advanced home healthcare in the Stockholm Region. A total of 30 Dosell pharmaceutical robots from iZafe have been purchased. During October, the pharmaceutical robot will be introduced to the first patient treated in advanced healthcare at home (ASIH).

— We see great opportunities with pharmaceutical robots in specialist healthcare. Innovation and technology that can help our patients to greater independence while increasing or maintaining patient safety is important to us, says Maria Frick.

It is the first time a pharmaceutical robot has been integrated into advanced home healthcare.

— We are extremely proud to continue to contribute to helping several patient groups and making everyday life easier with our unique pharmaceutical robot. We look forward to starting the implementation of Dosell at Aleris. After three months, an evaluation is carried out to see how many pharmaceutical robots the business wishes to bring in, says Anders Segerström, CEO iZafe Group.

For certain patient groups, the robot is an important aid. Last year, the poison information center received a number of calls about patients who, due to wrong dosage or mix-up, had taken the wrong medicine. 61 percent of them were recommended to seek medical care. Many serious overdoses are found in the group.

— A medication robot tells when a patient should take their medication, at the same time medication for future administration occasions is inaccessible, says Maria Frick.

Another advantage of pharmaceutical robots is increased efficiency and the opportunity to spend resources on more value-creating activities.

Not all patients in specialist healthcare are suitable for a medication robot, an assessment is always made and confirmed with the doctor that the patient can manage their medication with and that it is a suitable solution for this particular individual.

This is how a pharmaceutical robot works in specialist healthcare
The medication robot, no bigger than a shoebox, is placed in the patient's home. The robot is loaded with the patient's prescribed medication packaged in sachets. The medication robot reads the time for the next medication intake and at the correct date and time a dose bag is fed forward and thus becomes available to the patient. To remind you that it is time to take medicine, the robot signals with light and sound.

If for some reason the patient does not remove his dose bag from the robot, the patient's nurse will receive an alarm about this and then contact the patient, either through a phone call or a visit.

For further information contact:
Kenan Harbas, press manager Aleris, +46 707 834 203
Anders Segerström, CEO iZafe Group, +46 70-875 14 12

About Aleris
Aleri's vision is to lead the way to tomorrow's health and care. Through innovative solutions, we create opportunities for a better and healthier life while contributing to increased accessibility and social benefit. Aleris is a Scandinavian healthcare provider with two million patient visits a year and provides specialist healthcare at over 130 locations in Sweden, Norway and Denmark.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for residents in nursing homes. Dosell is integrated into welfare platforms and sold as one of several integrated digital aids via partners. Dosell notifies the patient when it is time to take the medication, and if the medication is not taken despite the reminders, Dosell alerts healthcare staff or relatives who can quickly prevent an injury from occurring as well as improve compliance and thereby minimize medication-related injuries.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe and Aleris start pilot projects for safer medication

iZafe and Aleris start pilot projects for safer medication

The Italian sachet market is starting to gain momentum

iZafe Group (publ.) hereby announces that the partner Remedio has sold its concept to 12 pharmacies which in a short time have 2,000 active customers who receive their medicines in sachets.

"Getting the medicine in sachets is completely new to the Italian market and our concept is based on local pharmacies purchasing a machine to enable their customers to have the medicine delivered in sachets. In a short time, we have now succeeded in installing machines for packing medicine into sachets in 12 pharmacies. These pharmacies have in turn gotten 2,000 of their customers to start getting their medicines delivered in sachets. Of these, about 95% are users in nursing homes. We currently have a rate of 2 new pharmacies a month installing a machine.
 
We will now start actively selling Dosell to these customers, but we will also start tests to introduce corportare version of Dosell, as most of our customers patients are now in nursing homes." says Alessandro Iadecola, CEO Remedio S.R.L.
 
 
"Getting several pharmacies to start packaging the medicines in sachets is absolutely crucial for Dosell, which is based on loading the medicine robot with these sachets. It will be exciting to follow the development on the Italian market, where it is now finally starting to gain momentum. Extra happy that so many nursing homes are starting to show interest in getting the medicine in sachets, as there are 3,000 nursing homes with over 300,000 beds in Italy." says Anders Segerström, CEO of iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The Italian sachet market is starting to gain momentum

The Italian sachet market is starting to gain momentum

The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022

Today, October 7, 2022, is the last day of trading with the warrants of series TO10B in iZafe Group AB (“iZafe” or “the Company”). The subscription period for the warrants of series TO10B runs up until October 11, 2022. Each warrant of series TO10B gives the owner the right to subscribe for one (1) new share of series B in iZafe. The exercise price for the warrants of series TO10B is SEK 0.26 per share of series B.

If all the warrants of series TO10B are exercised, the Company will receive approximately SEK 9.2 million before issuing costs. In order to prevent the warrants expiring without value, the holder must actively subscribe for new shares, no later than October 11, 2022. Alternatively, the holder may sell the warrants, no later than today, October 7, 2022. Please be aware that certain nominees may close their subscriptions earlier than October 11, 2022. Complete terms and conditions for the warrants are available on the Company’s website, www.izafegroup.com.

Summarized terms for the warrants of series TO10B:

Exercise period: September 27, 2022 – October 11, 2022.

Exercise price: SEK 0.26 per share of series B.

Issue size: 35,435,674 warrants of series TO10B, which entitles to subscription of 35,435,674 shares of series B. If all the warrants are exercised, The Company will receive approximately SEK 9.2 million before issuing costs.

Last day for trading warrants of series TO10B: October 7, 2022.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 7,087,134.80, from SEK 14,174,861.60 to SEK 21,261,996.40. If all warrants are exercised the number of shares will increase with 35,435,674 shares of series B, in total the number of shares in the Company will increase from 70,874,308 shares to 106,309,982 shares (600,000 shares of series A and 105,709,982 shares of series B). The dilution at full exercise of all warrants amounts to approximately 33.33 percent of the number of shares and 31.72 percent of the votes in the Company.
Note that the warrants of series TO10B that are not exercised at the latest October 11, 2022, or sold at the latest October 7, 2022, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022

The last day of trading with the warrants of series TO10B in iZafe Group AB is today, October 7, 2022

Kommuniké från extra bolagsstämma i iZafe Group AB

Extra bolagsstämman i iZafe Group AB, org. nr 556762–3391, ("Bolaget"), ägde rum idag den 5 oktober 2022. Extra bolagsstämman beslutade, med erforderlig majoritet, bland annat följande:

Val av antal ledamöter och av styrelseledamöter
Stämman beslutade att antalet styrelseledamöter ska uppgå till fem (5) utan suppleanter.

Det beslutades om nyval av Bosse Johansson, Magnus Engman och Björn Rosengren till ordinarie ledamöter av styrelsen. Beslutades att utse Björn Rosengren till styrelseordförande för tiden intill slutet av nästa årsstämma.

Beslut om långsiktigt incitamentsprogram till vissa anställda
Stämman beslutade att införa ett teckningsoptionsbaserat incitamentsprogram till anställda enligt styrelsens förslag, innebärande emission av högst 1 700 000 teckningsoptioner av serie TO11. Varje teckningsoption ger rätt att under nyttjandeperioden teckna en B-aktie i Bolaget till en teckningskurs motsvarande 200 procent av den volymvägda genomsnittskursen enligt Nasdaq:s officiella kurslista för aktien under de 10 handelsdagar som närmast föregick den extra bolagsstämman. Teckningskursen är således 0,88 kronor.

Nyteckning av aktier med stöd av teckningsoptionerna kan ske under perioden 1 november 2025–30 november 2025. Teckning av teckningsoptionerna ska ske till ett pris motsvarande teckningsoptionernas marknadsvärde med tillämning av vedertagen värderingsmetod (Black & Scholes-modellen).

Beslut om långsiktigt incitamentsprogram till styrelsens ledamöter
Stämman beslutade att införa ett teckningsoptionsbaserat incitamentsprogram till styrelsens ledamöter enligt valberedningens förslag, innebärande emission av högst 2 900 000 teckningsoptioner av serie TO12. Varje teckningsoption ger rätt att under nyttjandeperioden teckna en B-aktie i Bolaget till en teckningskurs motsvarande 200 procent av den volymvägda genomsnittskursen enligt Nasdaq:s officiella kurslista för aktien under de 10 handelsdagar som närmast föregick den extra bolagsstämman. Teckningskursen är således 0,88 kronor.

Nyteckning av aktier med stöd av teckningsoptionerna kan ske under perioden 1 november 2025–30 november 2025. Teckning av teckningsoptionerna ska ske till ett pris motsvarande teckningsoptionernas marknadsvärde med tillämning av vedertagen värderingsmetod (Black & Scholes-modellen).

Kontakter

Anders Segerström, Verkställande Direktör
Mail:
Mobilnummer: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-post:
www.izafe.se/investor-relations/

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafe Groups läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på www.izafe.se/investor-relations/.

Bifogade filer

Kommuniké från extra bolagsstämma i iZafe Group AB

Kommuniké från extra bolagsstämma i iZafe Group AB

iZafes valberedning föreslår ytterligare två styrelsekandidater

iZafe Group (publ) meddelar härmed att valberedningen föreslår att Bosse Johansson och Magnus Engman väljs in i styrelsen utöver Björn Rosengren

Till dagens extra stämma så har valberedningen fått två ytterligare kandidater som föreslås att väljas in på dagens extra stämma.
 
Bosse Johansson
Född 1965.
Civilekonom med inriktning mot bank och finans.
Stor erfarenhet från styrelseuppdrag och exekutiva roller inom bank samt på förtroendeposter inom idrottssverige på elitnivå. 
Bland annat som ordförande och verkställande direktör under 19 år för Sparbanken Sjuhärad AB samt styrelserna i Sparbankernas Riksförbund och huvudstyrelsen i Swedbank AB. 
13 år som ordförande för allsvenska fotbollsklubben IF Elfsborg. Tre år som ordförande för Svensk Elitfotboll och sedan 2022 ordförande för Brynäs IF.
 
 
Magnus Engman
Född 1967
En expert på att göra turnarounds och exits i mjukvarubranschen. Är idag Managing Director på SD Worx Sweden & Market Leader Nordic. Är ansvarig för ca 600 anställda och en omsättning på närmare en miljard. Tidigare roller
 
Valberedningens förslag till styrelse är
Göran Hermansson, styrelseledamot – omval
Richard Wolff, styrelseledamot – omval
Bosse Johansson, styrelseledamot – nyval
Magnus Engman, styrelseledamot – nyval
Björn Rosengren, styrelseordförande – nyval

Kontakter

Anders Segerström, Verkställande Direktör
Mail:
Mobilnummer: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-post:
www.izafe.se/investor-relations/

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafe Groups läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på www.izafe.se/investor-relations/.

Bifogade filer

iZafes valberedning föreslår ytterligare två styrelsekandidater

iZafes valberedning föreslår ytterligare två styrelsekandidater

Two municipalities choose to implement Dosell

iZafe Group (publ.) hereby announces that two municipalities in Sweden are choosing to implement Dosell now in October.

"We see an increased demand from municipalities that wish to implement Dosell, the period for implementation is short before the Christmas holiday starts, which means that we choose to start these two municipalities under our own auspices.
The municipalities will start with a low volume to find the right processes and routines to be able to introduce larger volumes of pharmaceutical robots. When the municipalities are to introduce several pharmaceutical robots, these will be handed over to our partners." Says Anders Segerström, CEO iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Two municipalities choose to implement Dosell

Two municipalities choose to implement Dosell
Webbdesign av Comlog Webbyrå Stockholm